BTIG Research Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price

Monopar Therapeutics (NASDAQ:MNPR) had its price target increased by analysts at BTIG Research from $117.00 to $133.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 15.87% from the company’s previous close.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Finally, Zacks Research raised Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $113.42.

Monopar Therapeutics Trading Up 0.3%

Shares of MNPR traded up $0.32 during trading hours on Wednesday, reaching $114.78. 306,811 shares of the company’s stock traded hands, compared to its average volume of 222,083. The stock has a market cap of $768.91 million, a PE ratio of -60.41 and a beta of 1.47. The firm’s 50 day simple moving average is $92.93 and its 200-day simple moving average is $70.68. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.13). As a group, analysts expect that Monopar Therapeutics will post -2.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in MNPR. Russell Investments Group Ltd. bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets grew its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Monopar Therapeutics in the 4th quarter worth $65,000. JPMorgan Chase & Co. raised its position in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics in the second quarter worth $80,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.